Navigation Links
Stem cells make bone marrow cancer resistant to treatment
Date:1/11/2008

lls act as cancer stem cells.

The Johns Hopkins scientists also compared the response of these special stem cells with the bulk of multiple myeloma plasma cells, to four different chemotherapy medications commonly used to treat patients with the disease: dexamethasone, lenadilomide, bortezomib and 4-hydroxycyclophosphamide. While all four agents significantly inhibited the growth of the plasma cells, none inhibited the stem cells.

To their surprise, the research team noted that the multiple myeloma stem cells resemble other types of adult stem cells and exhibit similar properties that may make them resistant to chemotherapy. They found that the stem cells contain high levels of enzymes that neutralize toxins, like cancer drugs, and expel them through miniature pumps on their cell surface. The investigators believe that these drug-fighting enzymes and pumps - also plentiful in normal stem cells - may help cancer stem cells resist treatment.

Nature made normal stem cells very hearty for a reason, namely to survive and help repair damaged tissues and organs after injury or illness, says William Matsui, M.D., an assistant professor of oncology at Hopkins and the studys lead investigator. To us, it makes sense that the same processes that protect normal stem cells also exist in cancer stem cells to make them resistant to chemotherapy. We need to develop new ways to target the specific biology of cancer stem cells to prevent the continued production of mature tumor cells and disease relapse.

Standard cancer therapy is like mowing the weed - it gets rid of the disease transiently but the dandelion always grows back. We need to get rid of the root to cure disease, and therefore need a different type of therapy - mowing wont work, says Jones.

Matsui says the work also may make it possible to track the rare myeloma stem cells as a marker of how well a patient is doing during treatment.

Multiple myeloma is the second
'/>"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Jefferson scientists find protein helps pancreatic cancer cells evade immune system and spread
2. New insight into factors that drive muscle-building stem cells
3. Forever young: Differentiation blocked in tumor stem cells
4. Some Immature Brain Cells May Promote Tumors
5. Localized Breast Cancer Cells Have Potential to Spread
6. FOXO factor promotes survival of oxygen-deprived cancer cells
7. Cancer stem cells: know thine enemy
8. Microchip Spots Stray Tumor Cells in the Bloodstream
9. Brain Cells More Powerful Than You Think
10. Microchip-based device can detect rare tumor cells in bloodstream
11. St. Jude finds link between cellular defense processes, showing how cancer cells survive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... is relative, especially to people who tend to be ... Medical Center in the US found that seven in ... People of normal weight make this mistake much less ... to misjudge their children,s size, as youngsters misjudge their ... at Weill-Cornell Medical College, in a study in the ...
(Date:9/16/2014)... study that compared patient-reported outcomes of a broad ... that single fraction radiation therapy (SFRT) is equally ... when pain, function and quality of life are ... American Society for Radiation Oncology,s (ASTRO,s) 56th Annual ... patients, pain, function and degree of distress were ...
(Date:9/16/2014)... While abnormalities in the adrenergic and noradrenergic systems, ... to play a role in the development of ... been no genetic evidence of this connection. A ... University,s Mailman School of Public Health and the ... ADRB2 gene and childhood adversity. For individuals with ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Beginning October 1st ... a new service offering for its clients who book a ... the volume of business they buy. Most recurring visit ... during the work week, but others include clients whose unique ... pet sitter on a daily basis. The newly ...
(Date:9/16/2014)... Philadelphia, PA (PRWEB) September 16, 2014 ... #1 Pain Management practice by Ranking Arizona magazine, has ... for implementation across its enterprise. , With TPC ... had a vast data repository that was managed through ... for both the management and clinical leadership teams. ...
Breaking Medicine News(10 mins):Health News:Poor body size judgement can lead to increased tolerance of obesity 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3
... , MORRISTOWN, N.J., Dec. 2 ... announced that the Federal Trade Commission (FTC) has accepted a ... acquisition of privately held Arrow Group and has granted early ... the parties to close the transaction. The parties have ...
... , NASHVILLE, Tenn., Dec. 2 ... company, has appointed Pearson Talbert as chief development officer. ... will provide leadership and vision to the sales and ... hospitals grow revenues through employer partnerships and physician relationships. ...
... , MORRISTOWN, N.J., Dec. 2 Watson Pharmaceuticals, Inc. (NYSE: ... the acquisition of Arrow Group for a combination of cash ... pharmaceutical company with over $3 billion in annual revenues and ... several significant benefits to Watson shareholders as a result of ...
... taking it for macular degeneration is not advised, ... Women who take low-dose aspirin to protect their heart ... new study by Harvard University researchers found what they ... age-related macular degeneration (AMD), an eye disease that destroys ...
... ... Lighting Sunday, December 13 to remember all children who died. Hundreds of services open to ... many believe is the world,s largest mass candle lighting. , ... Oak Brook IL (PRWEB) December 2, 2009 -- Tens of ...
... ... to do better, be better and take better self-care. What to do to ensure the ... make self-care the #1 priority. At Garden of Eve safe skin care is the primary ... consumer guide to safe cosmetic products. , ...
Cached Medicine News:Health News:Watson Receives FTC Clearance for Arrow Acquisition 2Health News:Aegis Health Group Hires Pearson Talbert as Chief Development Officer 2Health News:Watson Completes Acquisition of Arrow Group 2Health News:Watson Completes Acquisition of Arrow Group 3Health News:Watson Completes Acquisition of Arrow Group 4Health News:Watson Completes Acquisition of Arrow Group 5Health News:In Women, Aspirin Might Ward Off Eye Trouble 2Health News:Bereaved Families Unite for Compassionate Friends Worldwide Candle Lighting 2Health News:The New Year's Resolution that Fuels Them All: Self-Care; Garden of Eve Makes Self-Care Through Safe Skin Care # 1 Priority 2Health News:The New Year's Resolution that Fuels Them All: Self-Care; Garden of Eve Makes Self-Care Through Safe Skin Care # 1 Priority 3Health News:The New Year's Resolution that Fuels Them All: Self-Care; Garden of Eve Makes Self-Care Through Safe Skin Care # 1 Priority 4
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... DIEGO , Sept. 16, 2014 Imprimis ... pharmaceutical company dedicated to delivering high quality and novel ... announced that Chief Executive Officer Mark Baum ... Annual Craig-Hallum Alpha Select Conference in New York City.  ... its Go Dropless™ campaign in ophthalmology. The presentation ...
(Date:9/16/2014)... -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing ... today that it has entered into an agreement with ... of animal studies for levorphanol, the active ingredient of ... levorphanol.  Gavril Pasternak, MD, PhD, of MSKCC is the ... Pasternak said, "Levorphanol is a unique opioid analgesic that ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... COLLEGEVILLE, Pa., May 30 Wyeth,Pharmaceuticals, a ... today announced the,initiation of the INTORACT (INvestigation ... worldwide randomized, open-label, phase 3b,study comparing TORISEL(R) ... for first-line treatment of patients,with advanced renal ...
... evaluation of safety and tolerability, as ... 2 trials -, ROCKVILLE, Md., May 30 ... that it has initiated dosing in a Phase,1 clinical ... lead IAP,inhibitor, HGS1029, as monotherapy in patients with advanced ...
Cached Medicine Technology:Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 2Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 3Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 4Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 5Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 6Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 2Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 3Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: